Chicken or the egg: Warburg effect and mitochondrial dysfunction

F1000Prime Reports

Volumn 7, Issue , 2015, Pages

  Senyilmaz, Deniz ^a   Teleman, Aurelio A ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; PYRUVIC ACID;

CANCER CELL; CARCINOGENESIS; CELL METABOLISM; CELLULAR PARAMETERS; CITRIC ACID CYCLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY YIELD; GLYCOLYSIS; HUMAN; METABOLISM; MITOCHONDRIAL RESPIRATION; REVIEW; WARBURG EFFECT;

EID: 84928007579     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P7-41     Document Type: Review

References (110)

1. Warburg O: The Metabolism of Carcinoma Cells. J Cancer Res 1925, 9:148-63.
2. Warburg O: On the origin of cancer cells. Science 1956, 123:309-14.
3. Weinhouse S: The Warburg hypothesis fifty years later. Cancer Res Clin Oncol 1976, 87:115-26.
4. Weinhouse S: On respiratory impairment in cancer cells. Science 1956, 124:267-9.
5. Weinhouse S, Millington RH, Wenner CE: Metabolism of neoplastic tissue. I. The oxidation of carbohydrate and fatty acids in transplanted tumors. Cancer Res 1951, 11:845-50.
6. Sussman I, Erecinska M, Wilson DF: Regulation of cellular energy metabolism: the Crabtree effect. Biochim Biophys Acta 1980, 591:209-23.
7. Crabtree H.G: Observations on the carbohydrate metabolism of tumours. Biochem J 1929, 23:536-45.
8. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol 2006, 11:286-96.
9. Kitajima K, Suenaga Y, Kanda T, Miyawaki D, Yoshida K, Ejima Y, Sasaki R, Komatsu H, Saito M, Otsuki N, Nibu K, Kiyota N, Minamikawa T, Sugimura K: Prognostic value of FDG PET imaging in patients with laryngeal cancer. PLoS One 2014, 9: e96999.
10. Dooms C, van Baardwijk A, Verbeken E, van Suylen RJ, Stroobants S, De Ruysscher D, Vansteenkiste J: Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in earlystage non-small cell lung cancer. J Thorac Oncol 2009, 4:822-8.
11. Halfpenny W, et al.: FDG-PET. A possible prognostic factor in head and neck cancer. Br J Cancer 2002, 86:512-6.
12. Hatanaka M, Hain SF, Biassoni L, Maisey MN, Sherman JA, McGurk M: Transport of sugars in tumor cell membranes. Biochim Biophys Acta, 1974, 355(1): p. 77-104.
13. Szablewski L: Expression of glucose transporters in cancers. Biochim Biophys Acta 2013, 1835:164-9.
14. Medina RA, Owen GI: Glucose transporters: expression, regulation and cancer. Biol Res 2002, 35:9-26.
15. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A: Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001, 276:9519-25.
16. Murakami T, Nishiyama T, Shirotani T, Shinohara Y, Kan M, Ishii K, Kanai F, Nakazuru S, Ebina Y: Identification of two enhancer elements in the gene encoding the type 1 glucose transporter from the mouse which are responsive to serum, growth factor, and oncogenes. J Biol Chem 1992, 26:9300-6.
17. Ebert BL, Firth JD, Ratcliffe PJ: Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995, 270:29083-9.
18. Holman GD, Cushman SW: Subcellular localization and trafficking of the GLUT4 glucose transporter isoform in insulinresponsive cells. Bioessays 1994, 16:753-9.
19. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP Jr, Roth RA: Regulation of GLUT1 gene transcription by the serine/ threonine kinase Akt1. J Biol Chem 1999, 274:20281-6.
20. Wright EM: Glucose transport families SLC5 and SLC50. Mol Aspects Med 2013, 34:183-96.
21. Hardie DG, Ross FA, Hawley SA: AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012, 13:251-62.
22. Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25:4777-86.
23. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV: Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007, 27:7381-93.
24. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V: In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004, 377:347-55.
25. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
26. Bustamante E, Pedersen PL: High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 1977, 74:3735-9.
27. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH: Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002, 1555:14-20.
28. Funasaka T, Yanagawa T, Hogan V, Raz A: Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J 2005, 19:1422-30.
29. Filella X, Molina R, Jo J, Mas E, Ballesta AM: Serum phosphohexose isomerase activities in patients with colorectal cancer. Tumour Biol 1991, 1:360-7.
30. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E: The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 1990, 8:351-6.
31. Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR, Raz A: Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 1991, 266:13442-8.
32. Tsutsumi S, Yanagawa T, Shimura T, Fukumori T, Hogan V, Kuwano H, Raz A: Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem 2003, 278:32165-72.
33. Cabrera R, Baez M, Pereira HM, Caniuguir A, Garratt RC, Babul J: The crystal complex of phosphofructokinase-2 of Escherichia coli with fructose-6-phosphate: kinetic and structural analysis of the allosteric ATP inhibition. J Biol Chem 2011, 286:5774-83.
34. Kotlarz D, Buc H: Regulatory properties of phosphofructokinase 2 from Escherichia coli. Eur J Biochem 1981, 117:569-74.
35. Atkinson DE, Walton GM: Kinetics of Regulatory Enzymes. Escherichia Coli Phosphofructokinase. J Biol Chem 1965, 240:757-63.
36. Yalcin A, Telang S, Clem B, Chesney J: Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009, 86: 174-9.
37. Wu C, Khan SA, Peng LJ, Lange AJ: Roles for fructose-2,6-bisphosphate in the control of fuel metabolism: beyond its allosteric effects on glycolytic and gluconeogenic enzymes. Adv Enzyme Regul 2006, 46:72-88.
38. Kessler R, Bleichert F, Warnke JP, Eschrich K: 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) is up-regulated in high-grade astrocytomas. J Neurooncol 2008, 86:257-64.
39. Minchenko OH, Ochiai A, Opentanova IL, Ogura T, Minchenko DO, Caro J, Komisarenko SV, Esumi H: Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-4 in the human breast and colon malignant tumors. Biochimie 2005, 87:1005-10.
40. Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T, Kamata A, Sakamoto K, Nakanishi T, Kubo A, Hishiki T, Suematsu M: Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat Commun 2014, 5:3480.
41. Minchenko OI, Opentanova I, Caro J: Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett 2003, 554:264-70.
42. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, Toedt G, Campos B, Korshunov A, Momma S, Van Schaftingen E, Reifenberger G, Herold-Mende C, Lichter P, Radlwimmer B: RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 2012, 31:3235-43.
43. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A: Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2012, 2:328-43.
44. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH: TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 2006. 126(1): p. 107-20.
45. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH: Metabolic regulation by p53 family members. Cell Metab 2013, 18:617-33.
46. Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, Chen X, Zeng D, Tong A, Chen L, Wei Y, Huang C: Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 2010, 9:81.
47. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, Martinez D, Carnero A, Beach D: Glycolytic enzymes can modulate cellular life span. Cancer Res 2005, 65:177-85.
48. Hitosugi T, Zhou L, Elf S, Fan J, Kang HB, Seo JH, Shan C, Dai Q, Zhang L, Xie J, Gu TL, Jin P, Aleèkoviæ M, LeRoy G, Kang Y, Sudderth JA, DeBerardinis RJ, Luan CH, Chen GZ, Muller S, Shin DM, Owonikoko TK, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Ye K, Boggon TJ, Kang S, He C, Chen J: Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 2012, 22:585-600.
49. Cairns RA, Harris IS, Mak TW: Regulation of cancer cell metabolism. Nat Rev Cancer 2011, 11:85-95.
50. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-3.
51. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D: The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012, 53:421-36.
52. Deneke SM, Fanburg BL: Regulation of cellular glutathione. Am J Physiol 1989, 257:163-73.
53. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008, 452:181-6.
54. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC: Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010, 329:1492-9.
55. IsraelsenWJ, Dayton TL,Davidson SM, Fiske BP,HosiosAM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, JurczakMJ, DePinho RA, ClishCB, Jacks T, Kibbey RG,WulfGM,Di Vizio D, MillsGB,Cantley LC, Vander Heiden MG: PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 2013, 155:397-409.
56. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol (1985) 2000, 88:1474-80.
57. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV: c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997, 94:6658-63.
58. Fan J, Hitosugi T, Chung TW, Xie J, Ge Q, Gu TL, Polakiewicz RD, Chen GZ, Boggon TJ, Lonial S, Khuri FR, Kang S, Chen J: Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Mol Cell Biol 2011, 31:4938-50.
59. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, Royer RE, Vander Jagt DL, Semenza GL, Dang CV: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010, 107:2037-42.
60. Fantin VR, St-Pierre J, Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9(6):425-34.
61. Ullah MS, Davies AJ, Halestrap AP: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-7.
62. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouysségur J: CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 2011, 108:16663-8.
63. Halestrap AP, Brand MD, Denton RM: Inhibition of mitochondrial pyruvate transport by phenylpyruvate and alphaketoisocaproate. Biochim Biophys Acta 1974, 367:102-8.
64. Bricker DK, Taylor EB, Schell JC, Orsak T, Boutron A, Chen YC, Cox JE, Cardon CM, Van Vranken JG, Dephoure N, Redin C, Boudina S, Gygi SP, Brivet M, Thummel CS, Rutter J: A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012, 337:96-100.
65. Herzig S, Raemy E, Montessuit S, Veuthey JL, Zamboni N, Westermann B, Kunji ER, Martinou JC: Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337:93-6.
66. Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN, Metallo CM: Regulation of Substrate Utilization by the Mitochondrial Pyruvate Carrier. Mol Cell 2014, 56:425-35.
67. Yang C, Ko B, Hensley CT, Jiang L, Wasti AT, Kim J, Sudderth J, Calvaruso MA, Lumata L, Mitsche M, Rutter J, Merritt ME, DeBerardinis RJ: Glutamine Oxidation Maintains the TCA Cycle and Cell Survival during Impaired Mitochondrial Pyruvate Transport. Mol Cell 2014, 56:414-24.
68. Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, Egnatchik RA, Earl EG, DeBerardinis RJ, Rutter J: A Role for the Mitochondrial Pyruvate Carrier as a Repressor of the Warburg Effect and Colon Cancer Cell Growth. Mol Cell 2014, 56:400-413.
69. Holness MJ, Sugden MC: Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans 2003, 31:1143-51.
70. Sugden MC, Holness MJ: Recent advances in mechanisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 2003, 284:E855-62.
71. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC: HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006, 3:187-97.
72. Kim JW, Tchernyshyov I, Semenza GL, Dang CV: HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006, 3:177-85.
73. Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J: Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 2011, 44:864-77.
74. Fan J, Shan C, Kang HB, Elf S, Xie J, Tucker M, Gu TL, Aguiar M, Lonning S, Chen H, Mohammadi M, Britton LM, Garcia BA, Alečković M, Kang Y, Kaluz S, Devi N, Van Meir EG, Hitosugi T, Seo JH, Lonial S, Gaddh M, Arellano M, Khoury HJ, Khuri FR, Boggon TJ, Kang S, Chen J: Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Mol Cell 2014, 53:534-48.
75. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM: Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem J 1998, 329:191-6.
76. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
77. Knoechel TR, Tucker AD, Robinson CM, Phillips C, Taylor W, Bungay PJ, Kasten SA, Roche TE, Brown DG: Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands. Biochemistry 2006, 45:402-15.
78. Stacpoole PW: The pharmacology of dichloroacetate. Metabolism 1989, 38:1124-44.
79. Metallo CM, Vander Heiden MG: Understanding metabolic regulation and its influence on cell physiology. Mol Cell 2013, 49:388-98.
80. DeBerardinis RJ, Cheng T: Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010, 29:313-24.
81. Hensley CT, Wasti AT, DeBerardinis RJ: Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013, 123:3678-84.
82. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB: Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008, 105:18782-7.
83. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, Thompson CB: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007, 104:19345-50.
84. Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD: Quantitative flux analysis reveals folate-dependent NADPH production. Nature 2014, 510:298-302.
85. Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ: Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481:385-8.
86. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB: Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011, 108:19611-6.
87. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, Jewell CM, Johnson ZR, Irvine DJ, Guarente L, Kelleher JK, Vander Heiden MG, Iliopoulos O, Stephanopoulos G: Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012, 481:380-4.
88. Mullen AR, Hu Z, Shi X, Jiang L, Boroughs LK, Kovacs Z, Boriack R, Rakheja D, Sullivan LB, Linehan WM, Chandel NS, DeBerardinis RJ: Oxidation of alpha-ketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep 2014, 7:1679-90.
89. Gameiro PA, Laviolette LA, Kelleher JK, Iliopoulos O, Stephanopoulos G: Cofactor balance by nicotinamide nucleotide transhydrogenase (NNT) coordinates reductive carboxylation and glucose catabolism in the tricarboxylic acid (TCA) cycle. J Biol Chem 2013, 288:12967-77.
90. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O: In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013, 17:372-85.
91. Leonardi R, Subramanian C, Jackowski S, Rock CO: Cancerassociated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation. J Biol Chem 2012, 287:14615-20.
92. Mashima T, Seimiya H, Tsuruo T: De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-72.
93. Yang YA, Han WF, Morin PJ, Chrest FJ, Pizer ES: Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 2002, 279:80-90.
94. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB: ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005, 24:6314-22.
95. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17:225-34.
96. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-44.
97. Ye D, Xiong Y, Guan KL: The mechanisms of IDH mutations in tumorigenesis. Cell Res 2012, 22:1102-4.
98. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, JiangWQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19: 17-30.
99. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-67.
100. Baysal BE: On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003, 14:453-9.
101. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW 3rd, Cornelisse CJ, Devilee P, Devlin B: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287:848-51.
102. Tomlinson IP, AlamNA, Rowan AJ, Barclay E, Jaeger EE, KelsellD, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, HearleN, Houlston RS, KiuruM, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomäki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA; Multiple Leiomyoma Consortium: Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30:406-10.
103. Kaelin WG Jr., Ratcliffe PJ: Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008, 30:393-402.
104. Semenza GL: HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107:1-3.
105. Schofield CJ, Zhang Z: Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol 1999, 9:722-31.
106. Smith EH, Janknecht R, Maher LJ 3rd: Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 2007, 16:3136-48.
107. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E: Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7:77-85.
108. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP: Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005, 14:2231-9.
109. Morin A, Letouzé E, Gimenez-Roqueplo AP, Favier J: Oncometa-bolites-driven tumorigenesis: From genetics to targeted therapy. Int J Cancer 2014, 135:2237-48.
110. Vega-Naredo I, Loureiro R, Mesquita KA, Barbosa IA, Tavares LC, Branco AF, Erickson JR, Holy J, Perkins EL, Carvalho RA, Oliveira PJ: Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells. Cell Death Differ 2014, 21:1560-74.